instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
What was the outcome of reaction 'Renal failure'? | Heparin-Induced Thrombocytopenia After Mitral Valve Replacement.
Background: Heparin-induced thrombocytopenia (HIT) is a rare autoimmune reaction that involves a decrease in platelet count following heparin exposure and can be associated with life-threatening thrombosis. Because of their prolonged heparin exposure, pat... | Fatal | ReactionOutcome | CC BY | 34239383 | 19,619,076 | 2021 |
What was the outcome of reaction 'Renal tubular necrosis'? | Heparin-Induced Thrombocytopenia After Mitral Valve Replacement.
Background: Heparin-induced thrombocytopenia (HIT) is a rare autoimmune reaction that involves a decrease in platelet count following heparin exposure and can be associated with life-threatening thrombosis. Because of their prolonged heparin exposure, pat... | Fatal | ReactionOutcome | CC BY | 34239383 | 19,619,076 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pneumonia'. | Two cases of atypical femoral fracture in cancer patients administered with bone-modifying agents.
Objective: We report two cases of atypical femoral fracture (AFF) in patients with cancer. Patients: Two patients, a 53-year-old woman with breast cancer and a 77-year-old man with prostate cancer, could not walk after be... | DENOSUMAB | DrugsGivenReaction | CC BY-NC-ND | 34239630 | 19,657,273 | 2021-07 |
What is the weight of the patient? | Two cases of atypical femoral fracture in cancer patients administered with bone-modifying agents.
Objective: We report two cases of atypical femoral fracture (AFF) in patients with cancer. Patients: Two patients, a 53-year-old woman with breast cancer and a 77-year-old man with prostate cancer, could not walk after be... | 78 kg. | Weight | CC BY-NC-ND | 34239630 | 19,657,273 | 2021-07 |
What was the outcome of reaction 'Pneumonia'? | Two cases of atypical femoral fracture in cancer patients administered with bone-modifying agents.
Objective: We report two cases of atypical femoral fracture (AFF) in patients with cancer. Patients: Two patients, a 53-year-old woman with breast cancer and a 77-year-old man with prostate cancer, could not walk after be... | Fatal | ReactionOutcome | CC BY-NC-ND | 34239630 | 19,657,273 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product prescribing error'. | Vaping and Commitment Flu-B Infection Is a Deadly Combination for Spontaneous Pneumomediastinum.
Vaping or E-cigarettes were created to deliver nicotine-containing aerosol to users with a flavoring agent without agents such as tars, oxidant gases, and carbon monoxide smoke found in traditional tobacco cigarettes. The u... | OSELTAMIVIR | DrugsGivenReaction | CC BY | 34239752 | 20,142,927 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Treatment delayed'. | Vaping and Commitment Flu-B Infection Is a Deadly Combination for Spontaneous Pneumomediastinum.
Vaping or E-cigarettes were created to deliver nicotine-containing aerosol to users with a flavoring agent without agents such as tars, oxidant gases, and carbon monoxide smoke found in traditional tobacco cigarettes. The u... | OSELTAMIVIR | DrugsGivenReaction | CC BY | 34239752 | 20,142,927 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Acute kidney injury'. | A Rare Side Effect of Ibrutinib: Tumor Lysis Syndrome.
Chronic lymphocytic leukemia (CLL) is a progressive disease with an indolent course, and tumor lysis syndrome (TLS) is rarely seen in CLL. Ibrutinib is a novel bruton kinase (BTK) inhibitor increasingly used in CLL treatment. Ibrutinib has significant side effects ... | IBRUTINIB | DrugsGivenReaction | CC BY-NC | 34239769 | 19,609,585 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Anaemia'. | A Rare Side Effect of Ibrutinib: Tumor Lysis Syndrome.
Chronic lymphocytic leukemia (CLL) is a progressive disease with an indolent course, and tumor lysis syndrome (TLS) is rarely seen in CLL. Ibrutinib is a novel bruton kinase (BTK) inhibitor increasingly used in CLL treatment. Ibrutinib has significant side effects ... | IBRUTINIB | DrugsGivenReaction | CC BY-NC | 34239769 | 19,609,585 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Arthralgia'. | A Rare Side Effect of Ibrutinib: Tumor Lysis Syndrome.
Chronic lymphocytic leukemia (CLL) is a progressive disease with an indolent course, and tumor lysis syndrome (TLS) is rarely seen in CLL. Ibrutinib is a novel bruton kinase (BTK) inhibitor increasingly used in CLL treatment. Ibrutinib has significant side effects ... | IBRUTINIB | DrugsGivenReaction | CC BY-NC | 34239769 | 19,609,585 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Musculoskeletal pain'. | A Rare Side Effect of Ibrutinib: Tumor Lysis Syndrome.
Chronic lymphocytic leukemia (CLL) is a progressive disease with an indolent course, and tumor lysis syndrome (TLS) is rarely seen in CLL. Ibrutinib is a novel bruton kinase (BTK) inhibitor increasingly used in CLL treatment. Ibrutinib has significant side effects ... | IBRUTINIB | DrugsGivenReaction | CC BY-NC | 34239769 | 19,609,585 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Thrombocytopenia'. | A Rare Side Effect of Ibrutinib: Tumor Lysis Syndrome.
Chronic lymphocytic leukemia (CLL) is a progressive disease with an indolent course, and tumor lysis syndrome (TLS) is rarely seen in CLL. Ibrutinib is a novel bruton kinase (BTK) inhibitor increasingly used in CLL treatment. Ibrutinib has significant side effects ... | IBRUTINIB | DrugsGivenReaction | CC BY-NC | 34239769 | 19,609,585 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Tumour lysis syndrome'. | A Rare Side Effect of Ibrutinib: Tumor Lysis Syndrome.
Chronic lymphocytic leukemia (CLL) is a progressive disease with an indolent course, and tumor lysis syndrome (TLS) is rarely seen in CLL. Ibrutinib is a novel bruton kinase (BTK) inhibitor increasingly used in CLL treatment. Ibrutinib has significant side effects ... | IBRUTINIB | DrugsGivenReaction | CC BY-NC | 34239769 | 19,609,585 | 2021 |
What was the administration route of drug 'IBRUTINIB'? | A Rare Side Effect of Ibrutinib: Tumor Lysis Syndrome.
Chronic lymphocytic leukemia (CLL) is a progressive disease with an indolent course, and tumor lysis syndrome (TLS) is rarely seen in CLL. Ibrutinib is a novel bruton kinase (BTK) inhibitor increasingly used in CLL treatment. Ibrutinib has significant side effects ... | Oral | DrugAdministrationRoute | CC BY-NC | 34239769 | 19,609,585 | 2021 |
What was the outcome of reaction 'Acute kidney injury'? | A Rare Side Effect of Ibrutinib: Tumor Lysis Syndrome.
Chronic lymphocytic leukemia (CLL) is a progressive disease with an indolent course, and tumor lysis syndrome (TLS) is rarely seen in CLL. Ibrutinib is a novel bruton kinase (BTK) inhibitor increasingly used in CLL treatment. Ibrutinib has significant side effects ... | Recovered | ReactionOutcome | CC BY-NC | 34239769 | 19,609,585 | 2021 |
What was the outcome of reaction 'Anaemia'? | A Rare Side Effect of Ibrutinib: Tumor Lysis Syndrome.
Chronic lymphocytic leukemia (CLL) is a progressive disease with an indolent course, and tumor lysis syndrome (TLS) is rarely seen in CLL. Ibrutinib is a novel bruton kinase (BTK) inhibitor increasingly used in CLL treatment. Ibrutinib has significant side effects ... | Recovered | ReactionOutcome | CC BY-NC | 34239769 | 19,609,585 | 2021 |
What was the outcome of reaction 'Thrombocytopenia'? | A Rare Side Effect of Ibrutinib: Tumor Lysis Syndrome.
Chronic lymphocytic leukemia (CLL) is a progressive disease with an indolent course, and tumor lysis syndrome (TLS) is rarely seen in CLL. Ibrutinib is a novel bruton kinase (BTK) inhibitor increasingly used in CLL treatment. Ibrutinib has significant side effects ... | Recovered | ReactionOutcome | CC BY-NC | 34239769 | 19,609,585 | 2021 |
What was the outcome of reaction 'Tumour lysis syndrome'? | A Rare Side Effect of Ibrutinib: Tumor Lysis Syndrome.
Chronic lymphocytic leukemia (CLL) is a progressive disease with an indolent course, and tumor lysis syndrome (TLS) is rarely seen in CLL. Ibrutinib is a novel bruton kinase (BTK) inhibitor increasingly used in CLL treatment. Ibrutinib has significant side effects ... | Recovered | ReactionOutcome | CC BY-NC | 34239769 | 19,609,585 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Agitation'. | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | ACYCLOVIR, AMPHOTERICIN B, ARGININE, AVIBACTAM SODIUM\CEFTAZIDIME, CYCLOPHOSPHAMIDE, DEXTROSE, DOXYCYCLINE, FLUDARABINE PHOSPHATE, FOSCARNET, ISAVUCONAZOLE, LACOSAMIDE, LACTULOSE, LEVETIRACETAM, LEVOCARNITINE, LEVOFLOXACIN, LINEZOLID, MEROPENEM, METHYLPREDNISOLONE, PENTAMIDINE, PENTOBARBITAL, PROPOFOL, TOCILIZUMAB | DrugsGivenReaction | CC BY-NC | 34244183 | 19,778,946 | 2021-07-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Brain oedema'. | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | ACYCLOVIR, AMPHOTERICIN B, ARGININE, AVIBACTAM SODIUM\CEFTAZIDIME, CYCLOPHOSPHAMIDE, DEXTROSE, DOXYCYCLINE, FLUDARABINE PHOSPHATE, FOSCARNET, ISAVUCONAZOLE, LACOSAMIDE, LACTULOSE, LEVETIRACETAM, LEVOCARNITINE, LEVOFLOXACIN, LINEZOLID, MEROPENEM, METHYLPREDNISOLONE, PENTAMIDINE, PENTOBARBITAL, PROPOFOL, TOCILIZUMAB | DrugsGivenReaction | CC BY-NC | 34244183 | 19,778,946 | 2021-07-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cytokine release syndrome'. | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE | DrugsGivenReaction | CC BY-NC | 34244183 | 19,785,480 | 2021-07-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Depressed level of consciousness'. | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | ACYCLOVIR, AMPHOTERICIN B, ARGININE, AVIBACTAM SODIUM\CEFTAZIDIME, CYCLOPHOSPHAMIDE, DEXTROSE, DOXYCYCLINE, FLUDARABINE PHOSPHATE, FOSCARNET, ISAVUCONAZOLE, LACOSAMIDE, LACTULOSE, LEVETIRACETAM, LEVOCARNITINE, LEVOFLOXACIN, LINEZOLID, MEROPENEM, METHYLPREDNISOLONE, PENTAMIDINE, PENTOBARBITAL, PROPOFOL, TOCILIZUMAB | DrugsGivenReaction | CC BY-NC | 34244183 | 19,778,946 | 2021-07-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | ACYCLOVIR, AMPHOTERICIN B, ARGININE HYDROCHLORIDE, AVIBACTAM SODIUM\CEFTAZIDIME, DEXTROSE, DOXYCYCLINE HYCLATE, FOSCARNET, ISAVUCONAZOLE, LACOSAMIDE, LACTULOSE, LEVETIRACETAM, LEVOCARNITINE, LEVOFLOXACIN, LINEZOLID, MEROPENEM, METHYLPREDNISOLONE, OXYGEN, PENTAMIDINE, PENTOBARBITAL, PROPOFOL, SODIUM PHENYLBUTYRATE | DrugsGivenReaction | CC BY-NC | 34244183 | 19,628,311 | 2021-07-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Enterococcal bacteraemia'. | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE | DrugsGivenReaction | CC BY-NC | 34244183 | 19,785,480 | 2021-07-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Enterococcal infection'. | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | ACYCLOVIR, AMPHOTERICIN B, ARGININE, AVIBACTAM SODIUM\CEFTAZIDIME, CYCLOPHOSPHAMIDE, DEXTROSE, DOXYCYCLINE, FLUDARABINE PHOSPHATE, FOSCARNET, ISAVUCONAZOLE, LACOSAMIDE, LACTULOSE, LEVETIRACETAM, LEVOCARNITINE, LEVOFLOXACIN, LINEZOLID, MEROPENEM, METHYLPREDNISOLONE, PENTAMIDINE, PENTOBARBITAL, PROPOFOL, TOCILIZUMAB | DrugsGivenReaction | CC BY-NC | 34244183 | 19,778,946 | 2021-07-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Generalised oedema'. | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | ACYCLOVIR, AMPHOTERICIN B, ARGININE, AVIBACTAM SODIUM\CEFTAZIDIME, CYCLOPHOSPHAMIDE, DEXTROSE, DOXYCYCLINE, FLUDARABINE PHOSPHATE, FOSCARNET, ISAVUCONAZOLE, LACOSAMIDE, LACTULOSE, LEVETIRACETAM, LEVOCARNITINE, LEVOFLOXACIN, LINEZOLID, MEROPENEM, METHYLPREDNISOLONE, PENTAMIDINE, PENTOBARBITAL, PROPOFOL, TOCILIZUMAB | DrugsGivenReaction | CC BY-NC | 34244183 | 19,778,946 | 2021-07-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hepatic function abnormal'. | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | ACYCLOVIR, AMPHOTERICIN B, ARGININE, AVIBACTAM SODIUM\CEFTAZIDIME, CYCLOPHOSPHAMIDE, DEXTROSE, DOXYCYCLINE, FLUDARABINE PHOSPHATE, FOSCARNET, ISAVUCONAZOLE, LACOSAMIDE, LACTULOSE, LEVETIRACETAM, LEVOCARNITINE, LEVOFLOXACIN, LINEZOLID, MEROPENEM, METHYLPREDNISOLONE, PENTAMIDINE, PENTOBARBITAL, PROPOFOL, TOCILIZUMAB | DrugsGivenReaction | CC BY-NC | 34244183 | 19,778,946 | 2021-07-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypoalbuminaemia'. | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | ACYCLOVIR, AMPHOTERICIN B, ARGININE, AVIBACTAM SODIUM\CEFTAZIDIME, CYCLOPHOSPHAMIDE, DEXTROSE, DOXYCYCLINE, FLUDARABINE PHOSPHATE, FOSCARNET, ISAVUCONAZOLE, LACOSAMIDE, LACTULOSE, LEVETIRACETAM, LEVOCARNITINE, LEVOFLOXACIN, LINEZOLID, MEROPENEM, METHYLPREDNISOLONE, PENTAMIDINE, PENTOBARBITAL, PROPOFOL, TOCILIZUMAB | DrugsGivenReaction | CC BY-NC | 34244183 | 19,778,946 | 2021-07-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pancytopenia'. | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE | DrugsGivenReaction | CC BY-NC | 34244183 | 19,785,480 | 2021-07-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pyrexia'. | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE | DrugsGivenReaction | CC BY-NC | 34244183 | 19,785,480 | 2021-07-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Restlessness'. | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | ACYCLOVIR, AMPHOTERICIN B, ARGININE, AVIBACTAM SODIUM\CEFTAZIDIME, CYCLOPHOSPHAMIDE, DEXTROSE, DOXYCYCLINE, FLUDARABINE PHOSPHATE, FOSCARNET, ISAVUCONAZOLE, LACOSAMIDE, LACTULOSE, LEVETIRACETAM, LEVOCARNITINE, LEVOFLOXACIN, LINEZOLID, MEROPENEM, METHYLPREDNISOLONE, PENTAMIDINE, PENTOBARBITAL, PROPOFOL, TOCILIZUMAB | DrugsGivenReaction | CC BY-NC | 34244183 | 19,778,946 | 2021-07-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Sepsis'. | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | ACYCLOVIR, AMPHOTERICIN B, ARGININE, AVIBACTAM SODIUM\CEFTAZIDIME, CYCLOPHOSPHAMIDE, DEXTROSE, DOXYCYCLINE, FLUDARABINE PHOSPHATE, FOSCARNET, ISAVUCONAZOLE, LACOSAMIDE, LACTULOSE, LEVETIRACETAM, LEVOCARNITINE, LEVOFLOXACIN, LINEZOLID, MEROPENEM, METHYLPREDNISOLONE, PENTAMIDINE, PENTOBARBITAL, PROPOFOL, TOCILIZUMAB | DrugsGivenReaction | CC BY-NC | 34244183 | 19,778,946 | 2021-07-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Status epilepticus'. | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | ACYCLOVIR, AMPHOTERICIN B, ARGININE, AVIBACTAM SODIUM\CEFTAZIDIME, CYCLOPHOSPHAMIDE, DEXTROSE, DOXYCYCLINE, FLUDARABINE PHOSPHATE, FOSCARNET, ISAVUCONAZOLE, LACOSAMIDE, LACTULOSE, LEVETIRACETAM, LEVOCARNITINE, LEVOFLOXACIN, LINEZOLID, MEROPENEM, METHYLPREDNISOLONE, PENTAMIDINE, PENTOBARBITAL, PROPOFOL, TOCILIZUMAB | DrugsGivenReaction | CC BY-NC | 34244183 | 19,778,946 | 2021-07-08 |
What was the administration route of drug 'ARGININE'? | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | Other | DrugAdministrationRoute | CC BY-NC | 34244183 | 19,815,952 | 2021-07-08 |
What was the administration route of drug 'LACTULOSE'? | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | Oral | DrugAdministrationRoute | CC BY-NC | 34244183 | 19,778,946 | 2021-07-08 |
What was the administration route of drug 'OXYGEN'? | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | Nasal | DrugAdministrationRoute | CC BY-NC | 34244183 | 19,628,311 | 2021-07-08 |
What was the administration route of drug 'PROPOFOL'? | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | Other | DrugAdministrationRoute | CC BY-NC | 34244183 | 19,815,952 | 2021-07-08 |
What was the dosage of drug 'ARGININE'? | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | INFUSION | DrugDosageText | CC BY-NC | 34244183 | 19,778,946 | 2021-07-08 |
What was the dosage of drug 'DEXTROSE'? | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | INTRAVENOUS INFUSION | DrugDosageText | CC BY-NC | 34244183 | 19,778,946 | 2021-07-08 |
What was the dosage of drug 'LACOSAMIDE'? | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | HIGH?DOSE | DrugDosageText | CC BY-NC | 34244183 | 19,628,311 | 2021-07-08 |
What was the dosage of drug 'LEVETIRACETAM'? | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | HIGH?DOSE | DrugDosageText | CC BY-NC | 34244183 | 19,628,311 | 2021-07-08 |
What was the dosage of drug 'OXYGEN'? | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | 2 L OF CONTINUOUS OXYGEN VIA NASAL CANNULA | DrugDosageText | CC BY-NC | 34244183 | 19,628,311 | 2021-07-08 |
What was the dosage of drug 'TOCILIZUMAB'? | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | ONE DOSE | DrugDosageText | CC BY-NC | 34244183 | 19,778,946 | 2021-07-08 |
What was the outcome of reaction 'Agitation'? | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | Fatal | ReactionOutcome | CC BY-NC | 34244183 | 19,815,952 | 2021-07-08 |
What was the outcome of reaction 'Brain oedema'? | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | Fatal | ReactionOutcome | CC BY-NC | 34244183 | 19,815,952 | 2021-07-08 |
What was the outcome of reaction 'Depressed level of consciousness'? | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | Fatal | ReactionOutcome | CC BY-NC | 34244183 | 19,815,952 | 2021-07-08 |
What was the outcome of reaction 'Drug ineffective'? | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | Fatal | ReactionOutcome | CC BY-NC | 34244183 | 19,628,311 | 2021-07-08 |
What was the outcome of reaction 'Escherichia bacteraemia'? | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | Recovered | ReactionOutcome | CC BY-NC | 34244183 | 19,778,946 | 2021-07-08 |
What was the outcome of reaction 'Generalised oedema'? | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | Fatal | ReactionOutcome | CC BY-NC | 34244183 | 19,815,952 | 2021-07-08 |
What was the outcome of reaction 'Hepatic function abnormal'? | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | Fatal | ReactionOutcome | CC BY-NC | 34244183 | 19,815,952 | 2021-07-08 |
What was the outcome of reaction 'Hyperammonaemia'? | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | Fatal | ReactionOutcome | CC BY-NC | 34244183 | 19,778,946 | 2021-07-08 |
What was the outcome of reaction 'Hypoalbuminaemia'? | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | Fatal | ReactionOutcome | CC BY-NC | 34244183 | 19,815,952 | 2021-07-08 |
What was the outcome of reaction 'Pneumonia'? | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | Fatal | ReactionOutcome | CC BY-NC | 34244183 | 19,815,952 | 2021-07-08 |
What was the outcome of reaction 'Restlessness'? | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | Fatal | ReactionOutcome | CC BY-NC | 34244183 | 19,815,952 | 2021-07-08 |
What was the outcome of reaction 'Sepsis'? | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | Fatal | ReactionOutcome | CC BY-NC | 34244183 | 19,815,952 | 2021-07-08 |
What was the outcome of reaction 'Ureaplasma infection'? | Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication.
We report the first incidence of Ureaplasma infection causing lethal hyperammonemia in a chimeric receptor antigen T cell (CAR-T) recipient. A 53-year-old woman, after receiving CAR-T therapy, suf... | Fatal | ReactionOutcome | CC BY-NC | 34244183 | 19,815,952 | 2021-07-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | Itraconazole Improves Vulvodynia in Fungus Culture-Negative Patients Post Fluconazole Failure.
BACKGROUND
Vulvodynia is a difficult condition to treat due to both the uncertain etiology of the disorder and poorly available therapies. This difficulty leads to a disproportionately high prevalence and cost of treatment fo... | ITRACONAZOLE | DrugsGivenReaction | CC BY-NC-ND | 34246854 | 20,202,127 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Seizure'. | Itraconazole Improves Vulvodynia in Fungus Culture-Negative Patients Post Fluconazole Failure.
BACKGROUND
Vulvodynia is a difficult condition to treat due to both the uncertain etiology of the disorder and poorly available therapies. This difficulty leads to a disproportionately high prevalence and cost of treatment fo... | ITRACONAZOLE | DrugsGivenReaction | CC BY-NC-ND | 34246854 | 20,202,127 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Lower gastrointestinal haemorrhage'. | A Case of Massive Lower Gastrointestinal Bleed from a Cystic Artery Pseudoaneurysm Bleeding through a Cholecystocolic Fistula.
BACKGROUND Acute lower gastrointestinal bleeding (GIB) is often associated with favorable outcomes. It is readily diagnosed and managed with colonoscopy, or may resolve spontaneously. Rarely, e... | ASPIRIN, CLOPIDOGREL BISULFATE, RIVAROXABAN | DrugsGivenReaction | CC BY-NC-ND | 34247182 | 19,610,494 | 2021-07-11 |
What was the outcome of reaction 'Lower gastrointestinal haemorrhage'? | A Case of Massive Lower Gastrointestinal Bleed from a Cystic Artery Pseudoaneurysm Bleeding through a Cholecystocolic Fistula.
BACKGROUND Acute lower gastrointestinal bleeding (GIB) is often associated with favorable outcomes. It is readily diagnosed and managed with colonoscopy, or may resolve spontaneously. Rarely, e... | Recovered | ReactionOutcome | CC BY-NC-ND | 34247182 | 19,610,494 | 2021-07-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | Does ganciclovir exert retinal toxicity after multiple continuous intravitreal injections?
BACKGROUND
The objective of this study is to report a case of acute retinal necrosis in which abnormalities in visual function did not correspond to retinal anatomical outcomes.
METHODS
A 39-year-old female diagnosed with acute... | GANCICLOVIR | DrugsGivenReaction | CC BY | 34247579 | 19,618,028 | 2021-07-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use issue'. | Does ganciclovir exert retinal toxicity after multiple continuous intravitreal injections?
BACKGROUND
The objective of this study is to report a case of acute retinal necrosis in which abnormalities in visual function did not correspond to retinal anatomical outcomes.
METHODS
A 39-year-old female diagnosed with acute... | GANCICLOVIR | DrugsGivenReaction | CC BY | 34247579 | 19,618,028 | 2021-07-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Retinal injury'. | Does ganciclovir exert retinal toxicity after multiple continuous intravitreal injections?
BACKGROUND
The objective of this study is to report a case of acute retinal necrosis in which abnormalities in visual function did not correspond to retinal anatomical outcomes.
METHODS
A 39-year-old female diagnosed with acute... | GANCICLOVIR | DrugsGivenReaction | CC BY | 34247579 | 19,618,028 | 2021-07-12 |
What was the administration route of drug 'GANCICLOVIR'? | Does ganciclovir exert retinal toxicity after multiple continuous intravitreal injections?
BACKGROUND
The objective of this study is to report a case of acute retinal necrosis in which abnormalities in visual function did not correspond to retinal anatomical outcomes.
METHODS
A 39-year-old female diagnosed with acute... | Ophthalmic | DrugAdministrationRoute | CC BY | 34247579 | 19,618,028 | 2021-07-12 |
What was the dosage of drug 'GANCICLOVIR'? | Does ganciclovir exert retinal toxicity after multiple continuous intravitreal injections?
BACKGROUND
The objective of this study is to report a case of acute retinal necrosis in which abnormalities in visual function did not correspond to retinal anatomical outcomes.
METHODS
A 39-year-old female diagnosed with acute... | INTRAVITREAL GANCICLOVIR INJECTION 3 MG/0.1 ML, EVERY 2 WEEKS TO THE LEFT EYE | DrugDosageText | CC BY | 34247579 | 19,618,028 | 2021-07-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cytomegalovirus colitis'. | Immune Reconstitution Inflammatory Syndrome Associated with Pneumocystis Jirovecii Pneumonia and Cytomegalovirus Colitis in a Patient with Rheumatoid Arthritis.
A 68-year-old woman presenting with rheumatoid arthritis was admitted due to pancytopenia caused by methotrexate. Pneumocystis jirovecii pneumonia was diagnose... | ACTARIT, METHOTREXATE | DrugsGivenReaction | CC BY-NC-ND | 34248117 | 19,729,376 | 2021-07-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Immune reconstitution inflammatory syndrome'. | Immune Reconstitution Inflammatory Syndrome Associated with Pneumocystis Jirovecii Pneumonia and Cytomegalovirus Colitis in a Patient with Rheumatoid Arthritis.
A 68-year-old woman presenting with rheumatoid arthritis was admitted due to pancytopenia caused by methotrexate. Pneumocystis jirovecii pneumonia was diagnose... | ACTARIT, METHOTREXATE | DrugsGivenReaction | CC BY-NC-ND | 34248117 | 19,729,376 | 2021-07-10 |
What was the outcome of reaction 'Condition aggravated'? | Immune Reconstitution Inflammatory Syndrome Associated with Pneumocystis Jirovecii Pneumonia and Cytomegalovirus Colitis in a Patient with Rheumatoid Arthritis.
A 68-year-old woman presenting with rheumatoid arthritis was admitted due to pancytopenia caused by methotrexate. Pneumocystis jirovecii pneumonia was diagnose... | Recovering | ReactionOutcome | CC BY-NC-ND | 34248117 | 19,753,775 | 2021-07-10 |
What was the outcome of reaction 'Cytomegalovirus colitis'? | Immune Reconstitution Inflammatory Syndrome Associated with Pneumocystis Jirovecii Pneumonia and Cytomegalovirus Colitis in a Patient with Rheumatoid Arthritis.
A 68-year-old woman presenting with rheumatoid arthritis was admitted due to pancytopenia caused by methotrexate. Pneumocystis jirovecii pneumonia was diagnose... | Recovered | ReactionOutcome | CC BY-NC-ND | 34248117 | 19,729,376 | 2021-07-10 |
What was the outcome of reaction 'Immune reconstitution inflammatory syndrome'? | Immune Reconstitution Inflammatory Syndrome Associated with Pneumocystis Jirovecii Pneumonia and Cytomegalovirus Colitis in a Patient with Rheumatoid Arthritis.
A 68-year-old woman presenting with rheumatoid arthritis was admitted due to pancytopenia caused by methotrexate. Pneumocystis jirovecii pneumonia was diagnose... | Recovered | ReactionOutcome | CC BY-NC-ND | 34248117 | 19,729,376 | 2021-07-10 |
What was the outcome of reaction 'Pancytopenia'? | Immune Reconstitution Inflammatory Syndrome Associated with Pneumocystis Jirovecii Pneumonia and Cytomegalovirus Colitis in a Patient with Rheumatoid Arthritis.
A 68-year-old woman presenting with rheumatoid arthritis was admitted due to pancytopenia caused by methotrexate. Pneumocystis jirovecii pneumonia was diagnose... | Recovered | ReactionOutcome | CC BY-NC-ND | 34248117 | 19,729,376 | 2021-07-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Decreased appetite'. | Pneumocystis Pneumonia in a Patient with Ovarian Cancer Receiving Olaparib Therapy: A Case Report.
We herein report a case of pneumocystis pneumonia (PCP) in a 77-year-old woman with ovarian cancer who was receiving olaparib therapy. After the patient's second relapse of ovarian cancer, she was administered olaparib as... | CARBOPLATIN, CEFTRIAXONE, DOCETAXEL, OLAPARIB, PACLITAXEL, PREDNISOLONE, SULFAMETHOXAZOLE\TRIMETHOPRIM | DrugsGivenReaction | CC BY-NC-ND | 34248119 | 19,786,286 | 2021-07-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Lymphopenia'. | Pneumocystis Pneumonia in a Patient with Ovarian Cancer Receiving Olaparib Therapy: A Case Report.
We herein report a case of pneumocystis pneumonia (PCP) in a 77-year-old woman with ovarian cancer who was receiving olaparib therapy. After the patient's second relapse of ovarian cancer, she was administered olaparib as... | CARBOPLATIN, CEFTRIAXONE, DOCETAXEL, OLAPARIB, PACLITAXEL, PREDNISOLONE, SULFAMETHOXAZOLE\TRIMETHOPRIM | DrugsGivenReaction | CC BY-NC-ND | 34248119 | 19,786,286 | 2021-07-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pneumocystis jirovecii pneumonia'. | Pneumocystis Pneumonia in a Patient with Ovarian Cancer Receiving Olaparib Therapy: A Case Report.
We herein report a case of pneumocystis pneumonia (PCP) in a 77-year-old woman with ovarian cancer who was receiving olaparib therapy. After the patient's second relapse of ovarian cancer, she was administered olaparib as... | CARBOPLATIN, CEFTRIAXONE, DOCETAXEL, OLAPARIB, PACLITAXEL, PREDNISOLONE, SULFAMETHOXAZOLE\TRIMETHOPRIM | DrugsGivenReaction | CC BY-NC-ND | 34248119 | 19,786,286 | 2021-07-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Treatment failure'. | Pneumocystis Pneumonia in a Patient with Ovarian Cancer Receiving Olaparib Therapy: A Case Report.
We herein report a case of pneumocystis pneumonia (PCP) in a 77-year-old woman with ovarian cancer who was receiving olaparib therapy. After the patient's second relapse of ovarian cancer, she was administered olaparib as... | CARBOPLATIN, CEFTRIAXONE, DOCETAXEL, OLAPARIB, PACLITAXEL, PREDNISOLONE, SULFAMETHOXAZOLE\TRIMETHOPRIM | DrugsGivenReaction | CC BY-NC-ND | 34248119 | 19,786,286 | 2021-07-10 |
What was the administration route of drug 'PREDNISOLONE'? | Pneumocystis Pneumonia in a Patient with Ovarian Cancer Receiving Olaparib Therapy: A Case Report.
We herein report a case of pneumocystis pneumonia (PCP) in a 77-year-old woman with ovarian cancer who was receiving olaparib therapy. After the patient's second relapse of ovarian cancer, she was administered olaparib as... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 34248119 | 19,786,286 | 2021-07-10 |
What was the dosage of drug 'CARBOPLATIN'? | Pneumocystis Pneumonia in a Patient with Ovarian Cancer Receiving Olaparib Therapy: A Case Report.
We herein report a case of pneumocystis pneumonia (PCP) in a 77-year-old woman with ovarian cancer who was receiving olaparib therapy. After the patient's second relapse of ovarian cancer, she was administered olaparib as... | 4 CYCLICS | DrugDosageText | CC BY-NC-ND | 34248119 | 19,787,425 | 2021-07-10 |
What was the dosage of drug 'DOCETAXEL'? | Pneumocystis Pneumonia in a Patient with Ovarian Cancer Receiving Olaparib Therapy: A Case Report.
We herein report a case of pneumocystis pneumonia (PCP) in a 77-year-old woman with ovarian cancer who was receiving olaparib therapy. After the patient's second relapse of ovarian cancer, she was administered olaparib as... | 4 CYCLICS | DrugDosageText | CC BY-NC-ND | 34248119 | 19,787,425 | 2021-07-10 |
What was the dosage of drug 'PREDNISOLONE'? | Pneumocystis Pneumonia in a Patient with Ovarian Cancer Receiving Olaparib Therapy: A Case Report.
We herein report a case of pneumocystis pneumonia (PCP) in a 77-year-old woman with ovarian cancer who was receiving olaparib therapy. After the patient's second relapse of ovarian cancer, she was administered olaparib as... | 80 MILLIGRAM DAILY; | DrugDosageText | CC BY-NC-ND | 34248119 | 19,786,286 | 2021-07-10 |
What was the dosage of drug 'SULFAMETHOXAZOLE\TRIMETHOPRIM'? | Pneumocystis Pneumonia in a Patient with Ovarian Cancer Receiving Olaparib Therapy: A Case Report.
We herein report a case of pneumocystis pneumonia (PCP) in a 77-year-old woman with ovarian cancer who was receiving olaparib therapy. After the patient's second relapse of ovarian cancer, she was administered olaparib as... | 15 MG/KG DAILY; | DrugDosageText | CC BY-NC-ND | 34248119 | 19,786,286 | 2021-07-10 |
What was the outcome of reaction 'Decreased appetite'? | Pneumocystis Pneumonia in a Patient with Ovarian Cancer Receiving Olaparib Therapy: A Case Report.
We herein report a case of pneumocystis pneumonia (PCP) in a 77-year-old woman with ovarian cancer who was receiving olaparib therapy. After the patient's second relapse of ovarian cancer, she was administered olaparib as... | Recovering | ReactionOutcome | CC BY-NC-ND | 34248119 | 19,786,286 | 2021-07-10 |
What was the outcome of reaction 'Lymphopenia'? | Pneumocystis Pneumonia in a Patient with Ovarian Cancer Receiving Olaparib Therapy: A Case Report.
We herein report a case of pneumocystis pneumonia (PCP) in a 77-year-old woman with ovarian cancer who was receiving olaparib therapy. After the patient's second relapse of ovarian cancer, she was administered olaparib as... | Recovering | ReactionOutcome | CC BY-NC-ND | 34248119 | 19,786,286 | 2021-07-10 |
What was the outcome of reaction 'Pneumocystis jirovecii pneumonia'? | Pneumocystis Pneumonia in a Patient with Ovarian Cancer Receiving Olaparib Therapy: A Case Report.
We herein report a case of pneumocystis pneumonia (PCP) in a 77-year-old woman with ovarian cancer who was receiving olaparib therapy. After the patient's second relapse of ovarian cancer, she was administered olaparib as... | Recovering | ReactionOutcome | CC BY-NC-ND | 34248119 | 19,786,286 | 2021-07-10 |
What was the outcome of reaction 'Pneumonia bacterial'? | Pneumocystis Pneumonia in a Patient with Ovarian Cancer Receiving Olaparib Therapy: A Case Report.
We herein report a case of pneumocystis pneumonia (PCP) in a 77-year-old woman with ovarian cancer who was receiving olaparib therapy. After the patient's second relapse of ovarian cancer, she was administered olaparib as... | Recovering | ReactionOutcome | CC BY-NC-ND | 34248119 | 19,786,286 | 2021-07-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Optic Perineuritis Associated with Nivolumab Treatment for Non-Small Cell Lung Cancer.
We report the case of a 54-year-old man who was treated with nivolumab for recurrent squamous cell lung cancer. After 7 cycles of nivolumab treatment, the patient presented to our hospital with right eye vision loss. Gadolinium-enhan... | METHYLPREDNISOLONE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 34248541 | 20,018,972 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Optic perineuritis'. | Optic Perineuritis Associated with Nivolumab Treatment for Non-Small Cell Lung Cancer.
We report the case of a 54-year-old man who was treated with nivolumab for recurrent squamous cell lung cancer. After 7 cycles of nivolumab treatment, the patient presented to our hospital with right eye vision loss. Gadolinium-enhan... | NIVOLUMAB | DrugsGivenReaction | CC BY-NC | 34248541 | 17,133,367 | 2021 |
What was the administration route of drug 'METHYLPREDNISOLONE'? | Optic Perineuritis Associated with Nivolumab Treatment for Non-Small Cell Lung Cancer.
We report the case of a 54-year-old man who was treated with nivolumab for recurrent squamous cell lung cancer. After 7 cycles of nivolumab treatment, the patient presented to our hospital with right eye vision loss. Gadolinium-enhan... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 34248541 | 20,018,972 | 2021 |
What was the administration route of drug 'NIVOLUMAB'? | Optic Perineuritis Associated with Nivolumab Treatment for Non-Small Cell Lung Cancer.
We report the case of a 54-year-old man who was treated with nivolumab for recurrent squamous cell lung cancer. After 7 cycles of nivolumab treatment, the patient presented to our hospital with right eye vision loss. Gadolinium-enhan... | Intravenous drip | DrugAdministrationRoute | CC BY-NC | 34248541 | 17,133,367 | 2021 |
What was the administration route of drug 'PREDNISOLONE'? | Optic Perineuritis Associated with Nivolumab Treatment for Non-Small Cell Lung Cancer.
We report the case of a 54-year-old man who was treated with nivolumab for recurrent squamous cell lung cancer. After 7 cycles of nivolumab treatment, the patient presented to our hospital with right eye vision loss. Gadolinium-enhan... | Oral | DrugAdministrationRoute | CC BY-NC | 34248541 | 20,018,972 | 2021 |
What was the dosage of drug 'NIVOLUMAB'? | Optic Perineuritis Associated with Nivolumab Treatment for Non-Small Cell Lung Cancer.
We report the case of a 54-year-old man who was treated with nivolumab for recurrent squamous cell lung cancer. After 7 cycles of nivolumab treatment, the patient presented to our hospital with right eye vision loss. Gadolinium-enhan... | 3 MILLIGRAM/KILOGRAM, Q2WK | DrugDosageText | CC BY-NC | 34248541 | 17,133,367 | 2021 |
What was the outcome of reaction 'Optic perineuritis'? | Optic Perineuritis Associated with Nivolumab Treatment for Non-Small Cell Lung Cancer.
We report the case of a 54-year-old man who was treated with nivolumab for recurrent squamous cell lung cancer. After 7 cycles of nivolumab treatment, the patient presented to our hospital with right eye vision loss. Gadolinium-enhan... | Not recovered | ReactionOutcome | CC BY-NC | 34248541 | 17,133,367 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cholinergic syndrome'. | Alleviation of Abdominal Pain due to Irinotecan-Induced Cholinergic Syndrome Using Loperamide: A Case Report.
Irinotecan hydrochloride (irinotecan) is a chemotherapeutic agent used in the treatment of solid tumors. In addition to severe neutropenia and delayed diarrhea, irinotecan causes cholinergic syndrome, character... | ATROPINE SULFATE, CETUXIMAB, CHLORPHENIRAMINE MALEATE, DEXAMETHASONE, FLUOROURACIL, IRINOTECAN, LEVOLEUCOVORIN CALCIUM, MINOCYCLINE HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE, SCOPOLAMINE | DrugsGivenReaction | CC BY-NC | 34248544 | 19,692,880 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Alleviation of Abdominal Pain due to Irinotecan-Induced Cholinergic Syndrome Using Loperamide: A Case Report.
Irinotecan hydrochloride (irinotecan) is a chemotherapeutic agent used in the treatment of solid tumors. In addition to severe neutropenia and delayed diarrhea, irinotecan causes cholinergic syndrome, character... | ATROPINE SULFATE, CETUXIMAB, CHLORPHENIRAMINE MALEATE, DEXAMETHASONE, FLUOROURACIL, IRINOTECAN, LEVOLEUCOVORIN CALCIUM, MINOCYCLINE HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE, SCOPOLAMINE | DrugsGivenReaction | CC BY-NC | 34248544 | 19,692,880 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Palpitations'. | Alleviation of Abdominal Pain due to Irinotecan-Induced Cholinergic Syndrome Using Loperamide: A Case Report.
Irinotecan hydrochloride (irinotecan) is a chemotherapeutic agent used in the treatment of solid tumors. In addition to severe neutropenia and delayed diarrhea, irinotecan causes cholinergic syndrome, character... | ATROPINE SULFATE, CETUXIMAB, CHLORPHENIRAMINE MALEATE, DEXAMETHASONE, FLUOROURACIL, IRINOTECAN, LEVOLEUCOVORIN CALCIUM, MINOCYCLINE HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE, SCOPOLAMINE | DrugsGivenReaction | CC BY-NC | 34248544 | 19,692,880 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Respiratory disorder'. | Alleviation of Abdominal Pain due to Irinotecan-Induced Cholinergic Syndrome Using Loperamide: A Case Report.
Irinotecan hydrochloride (irinotecan) is a chemotherapeutic agent used in the treatment of solid tumors. In addition to severe neutropenia and delayed diarrhea, irinotecan causes cholinergic syndrome, character... | ATROPINE SULFATE, CETUXIMAB, CHLORPHENIRAMINE MALEATE, DEXAMETHASONE, FLUOROURACIL, IRINOTECAN, LEVOLEUCOVORIN CALCIUM, MINOCYCLINE HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE, SCOPOLAMINE | DrugsGivenReaction | CC BY-NC | 34248544 | 19,692,880 | 2021 |
What was the administration route of drug 'CHLORPHENIRAMINE MALEATE'? | Alleviation of Abdominal Pain due to Irinotecan-Induced Cholinergic Syndrome Using Loperamide: A Case Report.
Irinotecan hydrochloride (irinotecan) is a chemotherapeutic agent used in the treatment of solid tumors. In addition to severe neutropenia and delayed diarrhea, irinotecan causes cholinergic syndrome, character... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 34248544 | 19,692,880 | 2021 |
What was the administration route of drug 'DEXAMETHASONE'? | Alleviation of Abdominal Pain due to Irinotecan-Induced Cholinergic Syndrome Using Loperamide: A Case Report.
Irinotecan hydrochloride (irinotecan) is a chemotherapeutic agent used in the treatment of solid tumors. In addition to severe neutropenia and delayed diarrhea, irinotecan causes cholinergic syndrome, character... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 34248544 | 19,692,880 | 2021 |
What was the administration route of drug 'IRINOTECAN'? | Alleviation of Abdominal Pain due to Irinotecan-Induced Cholinergic Syndrome Using Loperamide: A Case Report.
Irinotecan hydrochloride (irinotecan) is a chemotherapeutic agent used in the treatment of solid tumors. In addition to severe neutropenia and delayed diarrhea, irinotecan causes cholinergic syndrome, character... | Other | DrugAdministrationRoute | CC BY-NC | 34248544 | 19,692,880 | 2021 |
What was the administration route of drug 'MINOCYCLINE HYDROCHLORIDE'? | Alleviation of Abdominal Pain due to Irinotecan-Induced Cholinergic Syndrome Using Loperamide: A Case Report.
Irinotecan hydrochloride (irinotecan) is a chemotherapeutic agent used in the treatment of solid tumors. In addition to severe neutropenia and delayed diarrhea, irinotecan causes cholinergic syndrome, character... | Oral | DrugAdministrationRoute | CC BY-NC | 34248544 | 19,692,880 | 2021 |
What was the administration route of drug 'PALONOSETRON HYDROCHLORIDE'? | Alleviation of Abdominal Pain due to Irinotecan-Induced Cholinergic Syndrome Using Loperamide: A Case Report.
Irinotecan hydrochloride (irinotecan) is a chemotherapeutic agent used in the treatment of solid tumors. In addition to severe neutropenia and delayed diarrhea, irinotecan causes cholinergic syndrome, character... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 34248544 | 19,692,880 | 2021 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.